This prospective, randomized, multicenter trial compared the efficacy of two antibiotic regimens for treatment of foot infections in diabetic adults. Patients with infections requiring hospitalization were randomized to receive either intravenous ofloxacin followed by oral ofloxacin or intravenous ampicillin/sulbactam followed by oral amoxicillin/clavulanate (the aminopenicillin regimen) for 14-28 days. Patients with osteomyelitis were eligible for the study if the infected bone was to be removed. Of 108 patients enrolled in the study, 88 who were evaluable had various skin and softtissue infections, and 24% had osteomyelitis. For the ofloxacin and aminopenicillin regimens, the mean duration of intravenous therapy was 7.8 and 7.1 days, respectively, the mean duration of oral therapy was 13.2 and 12.0 days, respectively, the rate of eradication of pathogens was 78% and 88%, respectively, and the overall rate of clinical cure or improvement was 85% and 83%, respectively. Thus, about 3 weeks of therapy with either regimen was well tolerated and effective in treating these diabetic foot infections.
Lower-extremity infections are a frequent problem in diabetic patients and are now the most common cause of hospitalization [1] [2] [3] [4] . Although some patients can be treated exclusively as outpatients, most are hospitalized initially for diagnostic studies and parenteral antibiotic therapy. In the past two decades, studies have helped to define the etiologic agents of these infections [1] , but there have been surprisingly few investigations of antimicrobial therapy [1] [2] [3] .
Among the previously published reports on the efficacy of antibiotic therapy for diabetic foot infections, only four were randomized, controlled trials: one exclusively enrolled outpatients with relatively mild infections [4] , two involved hospitalized patients with peripheral vascular disease [5, 6] , and one included only patients with limb-threatening infections [7] .
A variety of antibiotics, ranging from narrow-spectrum oral agents to broad-spectrum parenteral agents, were employed. Thus, few data are available to help clinicians determine the optimal choice of antimicrobial(s), the need for parenteral vs. oral agents, and the duration of therapy required for these infections. To address these issues, we conducted a prospective, Received 30 May 1996; revised 7 November 1996. Informed consent was obtained from the patients, and the guidelines for human experimentation of the U.S. Department of Health and Human Services and the authors' institutions were followed in the conduct of this clinical research.
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randomized, multicenter study of the efficacy of two relatively broad-spectrum therapeutic regimens administered parenterally initially and then orally.
Methods
Patients who had diabetes mellitus and a foot infection that required antibiotic therapy, as evidenced by purulent drainage, erythema, and swelling, and who were 18 years of age or older were potentially eligible for enrollment in the study. Patients were initially hospitalized usually because of the severity of their infection, an inability to ingest their medication, inadequate home support for wound care, or a need to monitor their response to therapy. Patients who had evidence of osteomyelitis, usually suspected because of clinical, laboratory, and plain radiograph findings, were not enrolled in the study unless all of the infected bone was to be removed soon after enrollment.
Other patients who were excluded from the study were those who had an infection known to be caused by a microorganism resistant to any of the study drugs, were allergic to any of the study drugs or related compounds, were grossly underweight, had a seizure or major psychiatric disorder, were pregnant or nursing, were undergoing renal dialysis, or were likely to die during the study. Written informed consent, approved by an investigational review board, was obtained from all subjects.
Patients who had received potentially effective antimicrobial therapy within 48 hours before presentation were not enrolled in the study unless there was documented failure of that therapy, as shown by the recovery of organisms from an active infection that were resistant to the drugs that they had received. Those patients who required a second systemic antimicrobial for any reason other than as defined below or who were receiv-CID 1997;24 (April) ing a topical antimicrobial at the site of infection were not enrolled in the study.
A history was obtained from all patients, and they all underwent a physical examination. This examination included a thorough scoring of the presence and severity of 12 signs and symptoms at the infected site. Plain roentgenograms of the affected foot were taken, and blood specimens were obtained for standard hematologic and serum chemistry tests; a urinalysis was also performed. Tissue specimens, needle aspirates, or swab specimens, samples that were most likely to provide reliable culture results, were obtained from the infected sites. These specimens were processed for isolation of aerobic, microaerophilic, and anaerobic microorganisms. Specimens were processed at the individual sites or were sent to a central laboratory. If bacteremia was suspected, three separate specimens of blood were cultured.
Patients were then randomly assigned to receive one of the following therapeutic regimens: ofloxacin-400 mg of ofloxacin intravenously that was changed when appropriate to 400 mg of ofloxacin orally every 12 hours; and aminopenicillin-1 -2 g of ampicillin/0.5 -1 g of sulbactam intravenously every 6 hours that was changed when appropriate to 500 mg of amoxicillin/125 mg of clavulanic acid orally every 8 hours. The initial dose of ampicillin/sulbactam was chosen by the investigator according to the severity of the infection. Subsequent doses of both ofloxacin and aminopenicillins were adjusted because of renal impairment according to the package circular.
If the patient's condition was not improving after appropriate wound care and initiation of antibiotic therapy, an additional antibiotic could be added to either regimen: metronidazole (for improved coverage of anaerobic bacteria) to the ofloxacin regimen, and gentamicin, trimethoprim-sulfamethoxazole, or another agent (for broader coverage of gram-negative bacilli) to the aminopenicillin regimen. The total duration of therapy was to be 14 to 28 days, as clinically indicated.
Any patient for whom culture of the admission specimen was sterile or yielded pathogens that were resistant to the study drugs or who developed osteomyelitis (as diagnosed by the investigator) during treatment with the study drugs was withdrawn from the study. A follow-up culture of a specimen from the infected site was done (if material was available) on the third to seventh day of the study and after completion of therapy. A follow-up set of blood cultures was performed if the initial blood culture was positive. Roentgenograms of the infected foot were taken again 2 to 3 weeks after study enrollment. The patient's response to therapy and any adverse events experienced were assessed on the third to seventh day of therapy. Each patient underwent a final evaluation 3 to 5 days after completion of antimicrobial therapy.
Clinical responses were defined as follows: cured, disappearance of all signs and symptoms associated with active infection; improved, incomplete abatement of the signs or symptoms; and failed, no improvement during therapy. Microbiological responses were defined as follows: cured, eradication of the original pathogen(s); partially cured, eradication of some but not all of the original pathogens; and failed, persistence of the original pathogen(s). Results were considered unevaluable if the initial culture was negative, if the patient received a nonstudy antimicrobial, or if there was another protocol violation. Superinfection was defined as the appearance of an active infection at any site that was due to a pathogen not previously isolated.
Results
During the 28-month period of this study, 108 patients were enrolled at 12 centers across the United States; 55 were randomized to receive the ofloxacin regimen, and 53 were randomized to receive the aminopenicillin regimen. The mean age of the patients was 61.5 years (range, 31-90 years), and 84% were men; the ethnicity of the patients was Caucasian for 54%, African American for 26%, and Hispanic for 20%. There were no statistically significant differences in the demographic characteristics of the patients randomized to receive the two therapeutic arms. Among 108 enrolled patients, 88 (81%) were evaluated for this report. The reasons for excluding 20 patients from the evaluation are shown in table 1.
The primary diagnoses present at the time of study enrollment are shown in table 2. A patient could have more than one of these diagnoses, but only one was designated as primary. As in most previous studies of diabetic foot infections, infection of a skin ulceration was the most common type of lesion followed by cellulitis [1, 3, 4] . By means of our scoring scheme, the severity of infections in the two treatment groups was similar. Ulcerations had a neuropathic component in 53% of cases and a vascular component in 19% of cases.
The severity of infections was, on average, nearly identical in the two treatment groups. The site of infection was most commonly on the toes (45% of cases), the plantar surface of the foot (12%), and the metatarsophalangeal joints (7%); other sites, or several areas, were involved in the remaining cases. Twenty-two patients had osteomyelitis. Osteomyelitis developed in one patient (who was treated with the aminopenicillin regimen) during therapy. As shown in table 3, osteomyelitis was noted at the time of study enrollment in 21 patients. Debridement of the affected bone was performed in 71% of cases.
Culture specimens were obtained by swabbing in 72% of cases, by needle aspiration in 9%, and by tissue sampling in 19%. The mean number of pathogens isolated from cultures of wound specimens taken at the time of enrollment of the evaluable patients was 1.6 (range, 0-7). Cultures of specimens obtained while the patients were receiving therapy yielded an average of 0.2 isolate, while those of specimens taken after completion of therapy yielded a mean of 0.1 isolate.
The specific microorganisms isolated from the infected sites are shown in table 4. Aerobic organisms accounted for 92% of the pathogens, and 67% were gram-positive cocci. Eleven The mean duration of therapy with the ofloxacin regimen was 7.8 days (range, 1-25 days) intravenously and 13.2 days (range, 3-25 days) orally. The mean duration of therapy with the aminopenicillin regimen was 7.1 days (range, 1-20 days) intravenously and 12.0 days (range, 1-24 days) orally. Patients with osteomyelitis received a somewhat longer course of intravenous therapy (mean duration, 9.2 vs. 7.0 days, respectively) but a slightly shorter course of oral therapy (mean duration, 11.5 vs. 12.9 days, respectively) than did patients with only soft-tissue infections. Thus, both therapeutic regimens were given to patients for a total duration of about 3 weeks.
The response to antibiotic therapy is shown in figure 1 . Therapy resulted in a cure or in improved conditions for 85% of the evaluable ofloxacin recipients and for 83% of the evaluable aminopenicillin recipients. Additional empirical therapy pro- viding coverage for anaerobic organisms was prescribed for only five (9%) of the subjects in the ofloxacin group; anaerobic organisms were isolated only from cultures of specimens from two of these patients. Additional coverage for aerobic gramnegative bacilli was added to the aminopenicillin regimen only twice: once before the patient started the regimen and once after the patient had concluded the regimen.
Only one pathogen, a Staphylococcus aureus isolate, showed resistance to ofloxacin; the patient from whom this isolate was recovered was withdrawn from the study. Three isolates, two S. aureus isolates and one Pseudomonas aeruginosa isolate, were resistant to the aminopenicillins. All three patients from whom these isolates were recovered were withdrawn from the study. Pathogens persisted in follow-up cultures of specimens from 11 ofloxacin recipients; three of these pathogens were S. aureus isolates, and eight were streptococcal species.
All of the patients from whom S. aureus isolates were recovered and two of the patients from whom streptococcal isolates were recovered were kept in the study; all of these patients were cured or showed improvement in their condition. Six of the eight patients from whom streptococcal isolates were recovered were removed from the study, and none clinically improved. Thus, all of the patients for whom cultures yielded aerobic gram-positive cocci improved clinically except for six (33%) of the 18 evaluable patients with streptococcal infections.
Pathogens persisted in cultures of specimens from four aminopenicillin recipients during therapy: three were S. aureus isolates and one was a coagulase-negative staphylococcus. All of these patients continued therapy with the study drug, and only the one from whom the coagulase-negative staphylococcus isolate was recovered improved. None of the patients from whom Enterococcus isolates were recovered had persistent infection with this organism. Overall, the rates of microbiological responses associated with the ofloxacin and aminopenicillin regimens were as follows: cured, 78% and 88%, respectively; and failed, 16% and 6%, respectively. The symptoms reported by patients during therapy are summarized in table 5. Potential side effects were experienced by 36% of the ofloxacin recipients and 22% of the aminopenicillin recipients (not a statistically significant difference). All but one of these events were classified as only "possibly" related to the study drugs; one patient's nausea was thought to be "probably" related to the aminopenicillin treatment. In the ofloxacin group, adverse events were characterized as "mild" in 74% of cases and as "moderate" in 26%; in the aminopenicillin group, the adverse events were characterized as "mild" in 50% of cases and as "moderate" in 50%. No adverse effect required discontinuation of therapy with the study drug.
Discussion
The optimal antimicrobial therapy for diabetic foot infections has yet to be defined. Because results of previous studies have suggested that a wide variety of both aerobic and anaerobic bacteria may be responsible for these infections, broadspectrum antibiotic therapy, often with two agents, has been recommended [3] . In most of these studies, the enrolled patients were hospitalized because of serious infections, which often had failed to respond to outpatient treatment. Patients with nonlimb-threatening infections who have not previously received antibiotic therapy, like most of the patients enrolled in this study, usually have infections caused by only one or two species of aerobic organisms [4] . While gram-positive cocci are the most common isolates, gram-negative pathogens are also isolated from more than one-quarter of patients. Furthermore, not all isolates, especially those from mixed infections, require specifically targeted therapy for eradication [8] .
The agents used in this study have a narrower antimicrobial spectrum than some antibiotics suggested for treatment of diabetic foot infections, but they provide appropriate coverage for the commonest isolates. The agents were selected, in part, because they have been shown in previous studies to be effective in treating diabetic foot infections [7, [9] [10] [11] . Compared with the aminopenicillins, ofloxacin has better oral bioavailability and improved activity against aerobic gram-negative bacilli but covers fewer anaerobes and gram-positive cocci.
Some investigators have suggested that the fluoroquinolones should not be used as single agents for treating diabetic foot infections, and for patients with potentially limb-threatening infections, they advocate combination therapy with clindamycin and a fluoroquinolone [3, 12] . The results of this and other studies [6, 11, 13, 14] , however, suggest that for most infections that are not immediately limb-or life-threatening, a fluoroquinolone alone may be effective therapy. In this study, good clinical results were obtained for 85% and 83% of subjects receiving ofloxacin and the aminopenicillins, respectively. These results are comparable with results of other reported series involving similar subjects [1, 3-6, 9, 13, 14] .
Of note is that in this study, unlike in many previous investigations, the number of bacterial isolates per case (1.6) was relatively low. This number is similar to that reported in another prospective trial involving patients with non-limb-threatening infections [4] but is lower than those reported in some trials, especially those in which all or most patients underwent limb amputations [1] . The patients in this study, while having infections severe enough to require hospitalization, did not usually have limb-threatening infections like those recently reported by Grayson et al. [7] . Even in their study, however, the mean number of bacterial pathogens per patient was only 2.8. Another difference between the current study and several previously published reports is that we isolated fewer anaerobic organisms [1, 3, 6, 13, 14] . Our culture specimens were obtained and processed appropriately to identify anaerobes, but it is possible that the shipping of culture specimens by some sites to a central laboratory led to some loss of relatively fastidious organisms.
We also found that persistence of microorganisms in followup cultures of specimens obtained during antibiotic therapy was infrequent and not necessarily associated with a failed clinical response. A few S. aureus isolates persisted in specimens from patients receiving both treatment regimens; those patients receiving ofloxacin therapy did well, while those receiving aminopenicillin treatment did not.
The persistence of streptococci in follow-up cultures of specimens from patients receiving ofloxacin therapy is of interest. It is unclear why one-third of these patients did not respond Table 5 . Possible adverse events reported by patients with diabetic foot infections who were enrolled in a trial of two parenteral-to-oral antibiotic regimens. 
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Improved to therapy, especially since patients from whom other grampositive cocci (including enterococci) were recovered did well. As other investigators have noted, however, patients often have a gOod clinical response even when some or all of the pathogens isolated from them are resistant to the antibiotic(s) that they are receiving [4, 7] .
Although this study was not designed to address therapy for pedal osteomyelitis in diabetic patients, this entity was diagnosed for more than one-fifth of our subjects. Diagnosing osteomyelitis in diabetic patients is difficult [1, 2] , and the criteria used in this study were those of the individual investigators. Nevertheless, it is interesting to note that the patients with osteomyelitis, who received the same 3-week total duration of therapy, had a good clinical response almost as often as those with only soft-tissue infection (71% vs. 85%, respectively). Surprisingly, bone debridement did not seem to improve the response (table 3), but the number of patients studied was too small to draw any conclusions. Most authorities recommend that patients with osteomyelitis have the infected bone debrided or resected if possible; if not, they should receive antibiotic therapy for a prolonged duration (6-12 weeks) [1, 8] .
To our knowledge, this is the largest published comparative study on antibiotic therapy for diabetic foot infections. It provides the experience of several centers and is one of the few prospective, randomized, controlled trials of specific antibiotic regimens. The results demonstrate that each of the therapeutic regimens used led to cure or improvement in most patients. The demographic characteristics of the patients studied and the types of infections with which they presented were similar to those described in most other studies. The frequency and severity of potential adverse events associated with the two regimens were similar and quite acceptable.
The cost of the two antibiotic regimens was nearly identical, but because ofloxacin is administered less frequently, it has the potential to reduce in-hospital administration costs and perhaps improve outpatient compliance. Hospitalization for diabetic foot infections is usually necessary only for patients with potentially limb-threatening infections or in other specific circumstances. The duration of intravenous therapy that was required for both regimens used in this study was only about 1 week, thereby suggesting that the duration of hospitalization needed for treatment of diabetic foot infections could be considerably shorter than previously reported [2, 4] . Further comparative trials are needed, however, to determine which antimicrobials may be the best choices in various clinical situations and how long patients should be treated.
